External validation of Adjuvant! Online breast cancer prognosis tool. prioritising recommendations for improvement

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Hajage, David ^a   de Rycke, Yann ^a   Bollet, Marc ^a   Savignoni, Alexia ^a   Caly, Martial ^a   Pierga, Jean Yves ^a   Horlings, Hugo M ^b   van de Vijver, Marc J ^b   Vincent Salomon, Anne ^a   Sigal Zafrani, Brigitte ^a   Senechal, Claire ^a   Asselain, Bernard ^a   Sastre, Xavier ^a   Reyal, Fabien ^a  

^a INSTITUT CURIE   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ACCURACY; ADJUVANT! ONLINE; ADULT; ALGORITHM; ARTICLE; BREAST CARCINOMA; CALIBRATION; CANCER GRADING; COMPUTER PROGRAM; FEMALE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL; VALIDATION PROCESS; BREAST TUMOR; COMPUTER AIDED DESIGN; FACTUAL DATABASE; FRANCE; MITOSIS; MORTALITY; NETHERLANDS; SURVIVAL; VALIDATION STUDY;

ALGORITHMS; BREAST NEOPLASMS; COMPUTER-AIDED DESIGN; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; INTERNET; KI-67 ANTIGEN; MITOSIS; NETHERLANDS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 80555145275     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027446     Document Type: Article

References (36)

1. Blamey RW, Davies CJ, Elston CW, Johnson J, Haybittle JL, et al. (1979) Prognostic factors in breast cancer - the formation of a prognostic index. Clin Oncol 5: 227-236.
2. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, et al. (1982) A prognostic index in primary breast cancer. Br J Cancer 45: 361-366.
3. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, et al. (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56: 489-492.
4. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, et al. (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991.
5. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942.
6. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467.
7. Early Breast Cancer Trialists' Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 355: 1757-1770.
8. Oakman C, Santarpia L, Di Leo A, (2010) Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 7: 725-732.
9. Campbell HE, Taylor MA, Harris AL, Gray AM, (2009) An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 101: 1074-1084.
10. Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, et al. (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 10: 1070-1076.
11. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, et al. (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23: 2716-2725.
12. Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, et al. (2009) Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 20: 258-264.
13. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW, (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107: 309-330.
14. van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, et al. (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23: 603-607.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43.
16. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
17. Cox DR, (1958) Two further applications of a model for binary regression. Biometrika 45: 562-565.
18. Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, et al. (2003) External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 56: 826-832.
19. Schemper M, (2003) Predictive accuracy and explained variation. Stat Med 22: 2299-2308.
20. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, et al. (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10: R93.
21. Lende TH, Janssen EAM, Gudlaugsson E, Voorhorst F, Smaaland R, et al. (2011) In Patients Younger Than Age 55 Years With Lymph Node-Negative Breast Cancer, Proliferation by Mitotic Activity Index Is Prognostically Superior to Adjuvant! Journal of Clinical Oncology 29: 852-858.
22. National Institute for Health and Clinical Excellence (2009) Available: http://www.nice.org.uk/nicemedia/pdf/CG80NICEGuideline.pdf.
23. Agarwal V, O'Neill P, (2011) Adjuvant! Online as a decision-making tool in early breast cancer-a UK national survey. Clin Oncol (R Coll Radiol) 23: 159-160.
24. National Comprehensive Cancer Network, (2011) National Comprehensive Cancer Network web site homepage. Available:http://wwwnccnorg/indexasp.
25. Balakrishnan A, Haysom SA, Ravichandran D, (2011) Adjuvant! Online does not significantly influence adjuvant chemotherapy decisions of a breast cancer multidisciplinary team (MDT): a prospective study. Ann Oncol 22: 1461-1462.
26. Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, et al. (2010) Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 46: 1382-1391.
27. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA, (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183.
28. Bedard PL, Cardoso F, (2011) Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? Nat Rev Clin Oncol 8: 272-279.
29. Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, et al. (2008) Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 13: 1235-1245.
30. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, et al. (2011) A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin Cancer Res 17: 6012-6020.
31. Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, et al. (2011) The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. Ann Oncol.
32. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS, (2011) Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol.
33. Beresford MJ, Wilson GD, Makris A, (2006) Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 8: 216.
34. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, et al. (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26: 5569-5575.
35. Ravdin PM, (1995) A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients. Bull Cancer 82 (Suppl 5): 561s-564s.
36. Ravdin PM, (1996) A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 23: 43-50.